Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms

被引：0
|
作者：
Xie, Zhuoer [1 ]
Chen, Evan C. C. [2 ,3 ]
Mendez, Lourdes M. [4 ,5 ]
Komrokji, Rami [1 ]
Zeidan, Amer M. [4 ,5 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol Dept, Tampa, FL USA
[2] Dana Farber Canc Inst, Dept Med Oncol, Adult Leukemia Program, Boston, MA USA
[3] Harvard Med Sch, Boston, MA USA
[4] Yale Univ, Yale Canc Ctr, Dept Internal Med, Sect Hematol,Sch Med, 37 Coll St,First Floor, New Haven, CT 06510 USA
[5] Yale Univ, Smilow Canc Hosp, Sch Med, 37 Coll St,First Floor, New Haven, CT 06510 USA
来源：
CANCER JOURNAL | 2023年 / 29卷 / 03期
关键词：
AML; CCUS; CHIP; CMUS; MDS; SOMATIC MUTATIONS; RISK; COMMON; CHIP; PREVALENCE; DYNAMICS; CELLS; MDS;
D O I：
10.1097/PPO.0000000000000656
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH management and research.
引用
收藏
页码：130 / 137
页数：8
相关论文
共 50 条
  • [1] Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms
    Charlotte K. Brierley
    David P. Steensma
    Current Hematologic Malignancy Reports, 2016, 11 : 408 - 415
  • [2] Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms
    Brierley, Charlotte K.
    Steensma, David P.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2016, 11 (06) : 408 - 415
  • [3] Autoimmunity, Clonal Hematopoiesis, and Myeloid Neoplasms
    Bekele, Delamo, I
    Patnaik, Mrinal M.
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2020, 46 (03) : 429 - +
  • [4] Dyserythropoiesis in the diagnosis of the myelodysplastic syndromes and other myeloid neoplasms: problem areas
    Goasguen, Jean E.
    Bennett, John M.
    Bain, Barbara J.
    Brunning, Richard
    Vallespi, Maria-Teresa
    Tomonaga, Masao
    Zini, Gina
    Renault, Alain
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 (04) : 526 - 533
  • [5] Clinical spectrum and clonal evolution in germline syndromes with predisposition to myeloid neoplasms
    Botero, Juliana Perez
    Ho, Thanh P.
    Hogan, William J.
    Kenderian, Saad
    Gangat, Naseema
    Tefferi, Ayalew
    Abraham, Roshini S.
    Phuong Nguyen
    Oliveira, Jennifer L.
    He, Rong
    Chen, Dong
    Viswanatha, David
    Rodriguez, Vilmarie
    Khan, Shakila P.
    Patnaik, Mrinal M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 (01) : 141 - 145
  • [6] Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
    Steensma, David P.
    Bejar, Rafael
    Jaiswal, Siddhartha
    Lindsley, R. Coleman
    Sekeres, Mikkael A.
    Hasserjian, Robert P.
    Ebert, Benjamin L.
    BLOOD, 2015, 126 (01) : 9 - 16
  • [7] Myeloid neoplasms and clonal hematopoiesis from the RUNX1 perspective
    Hayashi, Yoshihiro
    Harada, Yuka
    Harada, Hironori
    LEUKEMIA, 2022, 36 (05) : 1203 - 1214
  • [8] Myeloid neoplasms and clonal hematopoiesis from the RUNX1 perspective
    Yoshihiro Hayashi
    Yuka Harada
    Hironori Harada
    Leukemia, 2022, 36 : 1203 - 1214
  • [9] How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?
    Steensma, David P.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2021, 34 (04)
  • [10] Evolutionary trajectory from clonal hematopoiesis to therapy-related myeloid neoplasms
    Takahashi, Koichi
    CANCER SCIENCE, 2024, 115 : 773 - 773
12345